On June 2, American billionaire Elon Musk's neurotechnology startup Neuralink announced that it had completed a $650 million funding round.
This funding round - also known as Series E - saw participation from major US investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, among others.
Previously, in 2023, Neuralink raised $280 million in a Series D round, and a few months later added another $43 million.
In addition, Neuralink also said it has conducted more human clinical trials, implanting brain chips into five severely paralyzed individuals.
In May, Neuralink was approved by the US Food and Drug Administration (FDA) for inclusion in the Breakthrough Device Program.
According to the FDA, this is a voluntary program for certain medical devices and combination products that are intended to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions and diseases.
The program is designed to accelerate the development, evaluation and pre-market approval process, helping patients and healthcare providers gain timely access to advanced medical devices./.
Source: https://www.vietnamplus.vn/cong-ty-phu-elon-musk-neuralink-cua-ty-phu-elon-musk-hoan-tat-vong-goi-von-650-trieu-usd-post1042172.vnp
Comment (0)